Success Metrics

Clinical Success Rate
100.0%

Based on 16 completed trials

Completion Rate
100%(16/16)
Active Trials
16(47%)
Results Posted
50%(8 trials)

Phase Distribution

Ph not_applicable
2
6%
Ph phase_1
4
12%
Ph phase_3
6
18%
Ph phase_2
4
12%
Ph phase_4
3
9%

Phase Distribution

4

Early Stage

4

Mid Stage

9

Late Stage

Phase Distribution19 total trials
Phase 1Safety & dosage
4(21.1%)
Phase 2Efficacy & side effects
4(21.1%)
Phase 3Large-scale testing
6(31.6%)
Phase 4Post-market surveillance
3(15.8%)
N/ANon-phased studies
2(10.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

16 of 16 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

16

trials recruiting

Total Trials

34

all time

Status Distribution
Active(18)
Completed(16)

Detailed Status

Completed16
Recruiting9
Active, not recruiting7
Not yet recruiting2

Development Timeline

Analytics

Development Status

Total Trials
34
Active
16
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 14 (21.1%)
Phase 24 (21.1%)
Phase 36 (31.6%)
Phase 43 (15.8%)
N/A2 (10.5%)

Trials by Status

completed1647%
active_not_recruiting721%
recruiting926%
not_yet_recruiting26%

Recent Activity

Clinical Trials (34)

Showing 20 of 34 trialsScroll for more
NCT06372457

COLLIGO-HCM: A Multinational Observational Study of the Real-World Effectiveness of Mavacamten Among Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

Active Not Recruiting
NCT07557498

Mavacamten Outcomes in Hypertrophic Cardiomyopathy (HCM) and the Associated Patient and Physician Experiences in the US

Recruiting
NCT07004972Phase 4

A Study of Mavacamten in Adults With Obstructive Hypertrophic Cardiomyopathy in India (ROVER)

Active Not Recruiting
NCT07541833

Effectiveness and Treatment Patterns of Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan (MANAGE-HCM)

Recruiting
NCT07529938

Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy

Completed
NCT07361289

A Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy in China

Recruiting
NCT03723655Phase 2

A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM

Completed
NCT07383025

Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan

Recruiting
NCT05414175Phase 3

A Study of Mavacamten in Obstructive Hypertrophic Cardiomyopathy

Completed
NCT07103655Phase 4

The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction

Not Yet Recruiting
NCT06253221Phase 3

A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Active Not Recruiting
NCT06338202

Real-World Effectiveness of Mavacamten in Canada

Completed
NCT05582395Phase 3

A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy

Completed
NCT05489705

A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)

Recruiting
NCT05939700

Mavacamten Pregnancy Surveillance Program

Recruiting
NCT06112743Phase 4

A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Active Not Recruiting
NCT07168655

Mavacamten in Obstructive Hypertrophic Cardiomyopathy

Completed
NCT07107373

A Study to Assess the Treatment of Obstructive Hypertrophic Cardiomyopathy (oHCM) With Mavacamten in the US

Active Not Recruiting
NCT04349072Phase 3

A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy

Completed
NCT06947590Not Applicable

Efficacy of Mavacamten in Patients With Symptomatic Latent Obstructive Hypertrophic Cardiomyopathy

Active Not Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
34